Brain stimulation guided by brain scans to help movement recovery after ischemic stroke
Tests personalized brain stimulation versus a sham procedure in adults after ischemic stroke.
Plain-language title generated from the registry record
Registry title: A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-80 who had a stroke caused by a blocked blood vessel in the brain within the past 14 days. It tests brain stimulation guided by brain imaging.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Ischemic stroke that started within the past 14 days, on one side of the brain and above the brainstem, shown on CT or MRI. NIHSS score 6-25, with at least one arm or leg movement item scored 2 or more.
- Earlier treatment
- Before the stroke, the person had mRS 0-1 (no or very mild disability). Must not have joined another interventional study within 30 days.
Main reasons for not taking part
- Things that make magnetic brain stimulation (TMS) unsafe, such as metal in the skull, a pacemaker, an implanted drug pump or a cochlear implant
- History of epilepsy or seizures, brain tumor or other serious brain disease
- Stroke on both sides, or in the brainstem or cerebellum, or bleeding in the brain
- Blood pressure of 180 mmHg or higher (top number) or 110 mmHg or higher (bottom number) despite treatment
- Pregnant or breastfeeding, or planning pregnancy within 90 days
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07645560, who can take part
Where in China
- Beijing Tiantan HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07645560
- Record updated
- 18 August 2026
- Original description
This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.Read full original descriptionShow less
Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 2b Trial: MASTRE-2
This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.
Inclusion: Age 18-80 years; Ischemic stroke onset within the past 14 days; Unilateral, supratentorial ischemic stroke confirmed by CT or MRI; Pre-stroke modified Rankin Scale (mRS) score of 0-1; NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points; Written informed consent signed by the patient or the patient's legally authorized representative.
Exclusion: Concomitant malignant tumor or severe systemic disease with life expectancy < 90 days; Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study; Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant); History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease; Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage; Pre-stroke mRS ≥ 2; Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up; Midline shift or parenchymal mass effect on cranial CT or other imaging; CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum); Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment; Pregnant or breastfeeding women, or women planning pregnancy within 90 days.